Tag:
COPD
Latest Headlines
Latest Headlines
Elevation boasts 'gold standard' IIb data for COPD therapy
Today the biotech boasted that their therapy--EP-101--had registered positive data in a Phase IIb study, positioning it as a potential new "gold standard" in nebulized treatments for the ailment.
Inogen secures $20M for oxygen tech
Inogen has snagged $20 million in equity financing to help boost its position as a provider of oxygen technology in the homecare community. Novo A/S led the group of investors in the financing.
Novartis touts positive results for COPD inhalant
Novartis is reporting positive results from Phase III trials of QVA149, a COPD drug that uses the company's Breezhaler dry powder inhaler for delivery
Novartis posts promising Phase III results for blockbuster hopeful QVA149
Novartis touted a slate of positive results for its COPD blockbuster hopeful QVA149, heralding promising results from three Phase III studies.
GlaxoSmithKline undeterred by spotty results for Relovair
GlaxoSmithKline ( $GSK ) is pushing ahead with its plan to submit Relovair to regulators for approval this year.
Tracking inflammation in COPD
COPD leaves patients breathless and worsens over time, and according to the WHO, is likely be the third leading cause of death worldwide by 2030. Doctors currently use physical assessment to diagnose their patients, but adding in biomarkers could help them understand more about the outcomes for individuals.
With J&J deal undone, Orexo revamps drug delivery tech development
Sweden's Orexo will slash jobs and focus on three development programs that rely on enhancing already-approved treatments.
Mylan aims first Lexapro copy at Forest Labs
Good news for Mylan ( $MYL ), not so good for Forest Laboratories ( $FRX ).
Cincinnati Children's debuts new anti-inflammatory drug class
After mixed attempts by others in the past, scientists at Cincinnati Children's Hospital Medical Center say they've developed a new class of compounds designed to prevent inflammation leading...
Forest Labs notches victory en route to FDA ruling on COPD drug
Eyeing the major market for a chronic lung condition, Forest Laboratories ( $FRX ) picked up the backing of an FDA panel for its experimental COPD drug known as aclidinium. It's a key endorsement...
